This week, we gained important new ground in our work to advance the development of newcystic fibrosis treatments.
VX-809, a potential CF drug developed by Vertex Pharmaceuticals, showed encouraging results in a preliminary Phase 2a clinical trial.
VX-809 is one of the first investigational drugs aimed at treating the underlying causes of CF.
The oral therapy was tested in patient volunteers who have the most common cystic fibrosis mutation, Delta F508.
Results from the trial showed VX-809 was well-tolerated and, in a subset of CF patients, reduced sweat chloride levels — a key indicator of CF.
VX-809 is the direct result of one of the Foundation’s largest investments in drug development. This gives us confidence that our innovative approach to science leads to progress.
We ALL know money buys science and science buys HOPE!!!!
1 comment:
I saw this the other day on my Facebook page. Great news!
I hope the FDA doesn't do like they did with Aztreonam (Azli.) I know Aztreonam will be approved by the FDA, because there's too much positive data and an FDA Advisory Committee approved Azli for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with CF with a 15-1 vote. The one person who said 'no' can no longer be found. HAAHHAHAAHAHAHAH.
I guess the FDA wanted more 'data' a few months back. So they kinda had to take a small step back. The final ruling should be on February 13th 2010 according to their website, and those like myself who are in the Expanded Access Program, can continue to take Azli once it's passed.
Post a Comment